Neuroblastoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Condition:   Neuroblastoma Interventions:   Drug: Naxitamab monotherapy;   Drug: GM-CSF;   Drug: Irinotecan;   Drug: Temozolomide;   Drug: Naxitamab in combination therapy;   Drug: GM-CSF with combination regimen;   Drug: Sintilimab Sponsor:   Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials